In this issue:
Intermediate clinical endpoints in localised prostate cancer
Analysis of extended pelvic lymph node dissection
Serial molecular profiling and tumour upgrading
Statin use and outcomes after ADT
Gold fiducial markers effect on diffusion-weighted MRI
68Ga-PSMA-11 PET-CT prediction of response to ADT
Prostate radiofrequency focal ablation
Time in hormone-sensitive and castration-resistant disease states
Metastatic castrate-resistant prostate cancer after docetaxel + ADT
Pre-treatment MRI and oncologic outcomes after treatment
Please login below to download this issue (PDF)